AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
1.060
+0.030 (2.91%)
Mar 6, 2026, 4:00 PM EST - Market closed
Company Description
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder.
The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
AEON Biopharma, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Robert Bancroft |
Contact Details
Address: 5 Park Plaza, Suite 1750 Irvine, California 92614 United States | |
| Phone | 949 354 6499 |
| Website | aeonbiopharma.com |
Stock Details
| Ticker Symbol | AEON |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001837607 |
| CUSIP Number | 00791X209 |
| ISIN Number | US00791X2099 |
| Employer ID | 85-3940478 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert Bancroft | President, Chief Executive Officer and Director |
| Alex Wilson | Chief Legal and Strategy Officer and Corporate Secretary |
| Dr. Chad K. Oh M.D. | Chief Medical Officer |
| Jennifer Sy | Chief Accounting Officer and Principal Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 18, 2026 | 424B3 | Prospectus |
| Feb 17, 2026 | EFFECT | Notice of Effectiveness |
| Feb 9, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 29, 2026 | SCHEDULE 13D | Filing |
| Jan 29, 2026 | SCHEDULE 13D/A | Filing |
| Jan 21, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 29, 2025 | DEF 14A | Other definitive proxy statements |
| Dec 19, 2025 | PRE 14A | Other preliminary proxy statements |
| Dec 15, 2025 | 8-K | Current Report |